Skip to main content

Chronic Obstructive Pulmonary Disease clinical trials at UC Davis

6 research studies open to eligible people

Showing trials for
  • A Study of Experimental Tezepelumab for Chronic Obstructive Pulmonary Disease (COPD) Exacerbation

    open to eligible people ages 40-80

    A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2a Study to Explore the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

    Sacramento, California and other locations

  • A Study of the Experimental Medicine Alvelestat (MPH966) for Chronic Obstructive Pulmonary Disease (COPD)

    open to eligible people ages 18-75

    The purpose of this study is to investigate the effect of alvelestat (an oral neutrophil elastase inhibitor) on blood and sputum biomarkers in patients with PiZZ, null or rare variant phenotype/genotype alpha-1 anti-trypsin deficient lung disease. Change in a number of different blood and sputum biomarkers related to lung damage, inflammation and elastase activity will be measured over a 12 week period. The effect on lung function and respiratory symptoms will also be measured.

    Sacramento, California and other locations

  • A Study of the Safety and Effectiveness of Experimental Inhaled Treprostinil For Pulmonary Hypertension due to COPD

    open to eligible people ages 18 years and up

    This is a multicenter, randomized, double-blind, placebo-controlled, 30-week, adaptive cross-over study, with a Treatment Period of approximately 26 weeks under the Original Design or, if applicable, a 17-week parallel study, with a Treatment Period of approximately 14 weeks under the Contingent Design.

    Sacramento, California and other locations

  • Dose-Range Finding Study of the Effectiveness and Safety of Experimental QBW251 for COPD

    open to eligible people ages 40 years and up

    The purpose of this study is to support the dose selection for future studies by evaluating efficacy and safety of different QBW251 doses in COPD patients with chronic bronchitis and a history of exacerbations, compared to placebo, when added to a triple combination therapy of LABA, LAMA and ICS with respect to trough FEV1 change from baseline after 12 weeks of treatment.

    Medford, Oregon and other locations

  • Experimental Roflumilast or Azithromycin to Prevent COPD Exacerbations (RELIANCE)

    open to eligible people ages 40 years and up

    A multi-center, randomized, 36-month, parallel- group, non-inferiority, phase III study to compare the effectiveness of roflumilast (Daliresp, 500 mcg quaque die (QD) or alternate regimen) therapy versus azithromycin (250 mg QD, 500 mg QD three times per week, or alternate regimen) to prevent hospitalization or death in a patients at high risk for COPD exacerbations.

    Sacramento, California and other locations

  • Experimental Treatment With the "Hemolung" for Patients With COPD Hospitalized for Sudden and Severe Breathing Difficulty

    “This study will test the good and bad effects of using a new medical device called the Hemolung for patients with COPD.”

    open to eligible people ages 40 years and up

    This study evaluates the safety and efficacy of using the Hemolung RAS to provide low-flow extracorporeal carbon dioxide removal (ECCO2R) as an alternative or adjunct to invasive mechanical ventilation for patients who require respiratory support due to an acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD). It is hypothesized that the Hemolung RAS can be safely used to avoid or reduce time on invasive mechanical ventilation compared to COPD patients treated with standard-of-care mechanical ventilation alone. Eligible patients will be randomized to receive lung support with either the Hemolung RAS plus standard-of-care mechanical ventilation, or standard-of-care mechanical ventilation alone.

    Sacramento, California and other locations

Last updated: